Home / Health / Lung Cancer Drug Extends Survival Significantly
Lung Cancer Drug Extends Survival Significantly
25 Sep
Summary
- RYBREVANT therapy added 6.4 months to median overall survival.
- This combination offers the longest survival for this patient group.
- PFS2 improved by over 10 months with RYBREVANT combination.
New long-term data for Johnson & Johnson's RYBREVANT in advanced lung cancer are reinforcing its clinical value. In the final overall survival analysis of the PAPILLON study, patients with EGFR-mutated advanced non-small cell lung cancer receiving RYBREVANT plus chemotherapy experienced a median overall survival of 34.3 months.
This marks an improvement of 6.4 months compared to chemotherapy alone (27.9 months). Johnson & Johnson highlighted this as the longest median overall survival reported for this specific patient group, historically facing poorer outcomes with survival ranging from 16 to 24 months.
While crossover complicated the primary survival analysis, a prespecified analysis adjusted for this showed a 43% reduction in the risk of death. Progression-free survival through second disease progression (PFS2) also saw a substantial improvement, extending by over 10 months with the RYBREVANT combination.
These results complement earlier findings from the PAPILLON study's primary analysis, which had already supported global approvals for RYBREVANT in this setting. The drug is approved for multiple EGFR-mutated advanced NSCLC scenarios.
